Amgen, Inc. vs Dicks Sporting Goods Inc — how do they compare? Amgen, Inc. trades at $412.15 (market cap $224.14B), while Dicks Sporting Goods Inc trades at $205.76 (market cap $18.35B). The key difference: Amgen, Inc. is far larger — about 12.2× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| AMGN | DKS | |
|---|---|---|
Market Cap | $224.14B | $18.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $239.17 |
52-Week Low | $271.18 | $187.78 |
Enterprise Value | $267.45B | $25.14B |
Dividend Yield | 2.43% | 2.44% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →